Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma

Jodie L. Simpson, Joshua Daly, Katherine J. Baines, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Philip Hugenholtz, Dana Willner, Peter G. Gibson
European Respiratory Journal 2016 47: 792-800; DOI: 10.1183/13993003.00405-2015
Jodie L. Simpson
1Respiratory and Sleep Medicine, School of Medicine and Public Health, Centre for Asthma and Respiratory Disease, The University of Newcastle, Callaghan, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jodie.simpson@newcastle.edu.au
Joshua Daly
2Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences and Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine J. Baines
1Respiratory and Sleep Medicine, School of Medicine and Public Health, Centre for Asthma and Respiratory Disease, The University of Newcastle, Callaghan, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian A. Yang
3School of Medicine, The University of Queensland, St Lucia, Australia
4Dept of Thoracic Medicine, The Prince Charles Hospital, Chermside, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Upham
3School of Medicine, The University of Queensland, St Lucia, Australia
5Dept of Respiratory Medicine, Princess Alexandra Hospital, Woolloongabba, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Reynolds
6Dept of Thoracic Medicine, Royal Adelaide Hospital and Lung Research Laboratory, Hanson Institute, Adelaide, Australia
7School of Medicine, The University of Adelaide, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Hodge
6Dept of Thoracic Medicine, Royal Adelaide Hospital and Lung Research Laboratory, Hanson Institute, Adelaide, Australia
7School of Medicine, The University of Adelaide, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan L. James
8Dept of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
9School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Hugenholtz
2Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences and Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Willner
2Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences and Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter G. Gibson
1Respiratory and Sleep Medicine, School of Medicine and Public Health, Centre for Asthma and Respiratory Disease, The University of Newcastle, Callaghan, Australia
10Woolcock Institute of Medical Research, Glebe, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Additional Files
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Heatmap showing the relative abundances of the dominant bacterial operational taxonomical units. f_: family; c_: class.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Principal component analysis plot. The axes represent each of the principal components (PC1 and PC2) and the proportion of the variation explained is shown in brackets. OTU: operational taxonomic unit.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Clinical and inflammatory cell parameters of participants with neutrophilic and non-neutrophilic asthma

    NeutrophilicNon-neutrophilicp-value
    Subjects720
    Age years50.7±9.760.3±10.80.049
    Male15 (71)6 (30)0.071
    Atopic6 (86)16 (80)0.713
    Ex-smoker2 (29)11 (55)0.224
    Smoking pack-years1 and 2416.8 (2.2, 56.5)0.621
    FEV1 % predicted84.2 (17.0)74.3 (17.8)0.213
    FEV1/FVC %74.8±7.566.8±10.00.064
    ACQ6 score1.0±0.71.4±1.00.342
    GINA treatment step0.562
     10 (0)1 (5)
     20 (0)0 (0)
     31 (17)1 (5)
     45 (83)18 (90)
    Taking ICS6 (86)18 (90)0.610
    ICS dose µg2000 (800, 2000)2000 (1000, 2000)0.933
    VAS symptom scores
     Breathlessness4.1 (1.1, 23)7.2 (4.8, 10.0) (n=19)0.341
     Wheeze1.1 (0.1, 7.0)3.5 (1.0, 6.4) (n=19)0.469
     Cough4.5 (2.2, 51)7.5 (2.8, 10.0) (n=19)0.665
     Sputum production3.0 (0.7, 14.0)5.9 (0.7, 10.0) (n=19)0.729
    Inflammatory cell counts
     Total cell count ×106 mL–17.2 (6.7, 9.1)3.2 (2.1, 5.0)0.015
     Viability %84 (81, 94)78 (73, 83)0.064
     Neutrophils %74.4±12.230.0±16.7<0.001
     Eosinophils %0.3 (0.0, 1.0)2.1 (0.9, 4.4)0.016
     Macrophages %21.5 (14.8, 34.8)52.7 (41.6, 68.9)<0.001
     Lymphocytes %0.5 (0.0, 1.75)1.0 (0.3, 1.1)0.538
     Columnar epithelial cells %0.3 (0.0, 1.0)1.9 (0.9, 4.9)<0.001
     Squamous cells %1.2 (0.0, 11.3)4.7 (1.4, 8.6)
    • Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; GINA: Global Initiative for Asthma; ICS: inhaled corticosteroid; VAS: visual analogue scale.

  • TABLE 2

    Sputum sample bacterial diversity and phyla for adults with neutrophilic and non-neutrophilic asthma

    NeutrophilicNon-neutrophilicp-value
    Subjects720
    Shannon index1.1 (0.9, 4.2)3.8 (3.4, 4.2)0.010
    Simpson index0.3 (0.3, 0.9)0.9 (0.8, 0.9)0.035
    Bacteria phyla
     Actinobacteria3.8 (0.2, 3.1)4.0 (2.1, 6.7)0.019
     Bacteroidetes2.3 (1.1, 26.7)14.9 (8.4, 22.8)0.092
     Firmicutes7.8 (3.1, 25.7)35.8 (27.5, 41.8)0.009
     Fusobacteria0.5 (0.3, 3.8)3.7 (2.3, 7.8)0.103
     Proteobacteria88.0 (25.1, 92.0)38.0 (21.1, 43.1)0.046
    • Data are presented as n or median (quartile 1, quartile 3), unless otherwise stated.

  • TABLE 3

    Sputum sample bacterial diversity and phyla for ex-smokers and never-smokers

    Ex-smokerNever-smokerp-value
    Subjects1614
    Shannon index3.8 (3.5, 4.4)2.8 (1.1, 4.1)0.010
    Simpson index0.9 (0.8, 0.9)0.7 (0.3, 0.9)0.040
    Bacteria phyla
     Actinobacteria4.0 (2.0, 7.5)2.6 (0.3, 4.5)0.077
     Bacteroidetes14.5 (8.4, 23.9)9.1 (1.1, 22.9)0.299
     Firmicutes32.4 (26.3, 37.2)21.2 (5.4, 40.7)0.271
     Fusobacteria4.0 (3.4, 9.3)2.1 (0.4, 5.0)0.028
     Proteobacteria41.5 (22.6, 43.1)60.3 (21.3, 91.4)0.360
    • Data are presented as n or median (quartile 1, quartile 3), unless otherwise stated.

  • TABLE 4

    Clinical and inflammatory characteristics of participants with and without Tropheryma sequences

    Tropheryma presentTropheryma absentp-value
    Subjects723
    Age years53±1460±90.175
    Male2 (29)10 (43)0.403
    Atopic5 (71)19 (87)0.347
    Ex-smoker4 (57)12 (52)0.581
    Smoking pack-years16.7 (7.7, 47.8)14.4 (1.3, 40.3)0.505
    FEV1 % predicted81±2476±150.577
    FEV1/FVC %71±1068±100.517
    ICS dose µg2000 (2000, 4000)2000 (1000, 2000)0.150
    ACQ6 score1.0±0.71.5±1.00.250
    VAS symptom scores
     Breathlessness6.5 (2.1, 23.0)7.0 (4.1, 10.0)1.000
     Wheeze3.5 (1.0, 4.6)3.2 (0.8, 6.7)0.683
     Cough6.0 (3.7, 7.2)7.4 (2.2, 10.0)0.386
     Sputum production3.8 (0.0, 5.9)4.7 (1.8, 10.0)0.740
    Inflammatory cell counts
     Total cell count ×106 mL–15.2 (3.3, 7.2)4.6 (2.2, 8.9)0.713
     Viability %85 (74, 94)81 (75, 84)0.328
     Neutrophils %40.9±25.541.8±25.70.942
     Eosinophils %1.8 (1.0, 7.0)1.5 (0.3, 4.0)0.769
     Macrophages %45 (35, 77)41 (21, 61)0.419
     Lymphocytes %1.0 (0.3, 2.5)0.5 (0.3, 1.0)0.457
     Columnar epithelial cells %0.5 (0.3, 2.5)1.3 (0.3, 3.0)0.475
     Squamous cells %6.8 (1.5, 9.5)3.6 (0.5, 6.3)0.154
    • Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; ICS: inhaled corticosteroid; VAS: visual analogue scale.

  • TABLE 5

    Clinical and inflammatory characteristics of participants with and without a high abundance of Haemophilus sequences (Haemophilus high and Haemophilus low groups)

    Haemophilus highHaemophilus lowp-value
    Subjects624
    Age years45±1462±7<0.001
    Male5 (83)7 (29)0.026
    Atopic6 (100)18 (78)0.283
    Ex-smoker0 (0)16 (67)0.005
    Smoking pack-years14.4 (1.9, 40.3)
    FEV1 % predicted82.2±14.276.2±17.90.452
    FEV1/FVC %73.2±8.8)67.6±10.50.241
    ICS dose µg2000 (2000, 2000)2000 (900, 2000)0.393
    ACQ6 score1.19±0.681.44±1.000.571
    VAS symptom scores
     Breathlessness2.8 (1.1, 8.0)7.0 (4.8, 18.0)0.077
     Wheeze1.1 (0.8, 2.0)4.0 (1.1, 7.0)0.063
     Cough5.0 (3.0, 6.0)7.2 (1.8, 10.0)0.706
     Sputum production2.7 (0.7, 3.3)5.9 (1.8, 10.0)0.215
    Inflammatory cell counts
     Neutrophilic asthma4 (67)3 (15)0.024
     Total cell count ×106 mL–17.0 (3.5, 8.4)4.4 (2.5, 8.6)0.568
     Viability %82 (75, 84)82 (76, 90)0.484
     Neutrophils %61.2±33.635.9±19.80.027
     Eosinophils %1.3 (0.3, 4.3)1.6 (0.5, 3.6)0.917
     Macrophages %23.8 (14.8, 42.3)46.3 (34.8, 62.5)0.087
     Lymphocytes %1.5 (0.5, 2.5)0.5 (0.3, 1.0)0.104
     Columnar epithelial cells %0.4 (0.3, 1.0)1.8 (0.4, 3.3)0.152
     Squamous cells %5.6 (1.0, 9.9)3.7 (1.1, 7.0)0.622
    • Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; ICS: inhaled corticosteroid; VAS: visual analogue scale.

Additional Files

  • Figures
  • Tables
  • Disclosures

    • J. Daly
    • P.G. Gibson
    • S. Hodge
    • J.L. Simpson
    • J.W. Upham
    • I.A. Yang
  • Supplementary material

    Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

    • Supplementary material
PreviousNext
Back to top
View this article with LENS
Vol 47 Issue 3 Table of Contents
European Respiratory Journal: 47 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma
Jodie L. Simpson, Joshua Daly, Katherine J. Baines, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Philip Hugenholtz, Dana Willner, Peter G. Gibson
European Respiratory Journal Mar 2016, 47 (3) 792-800; DOI: 10.1183/13993003.00405-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma
Jodie L. Simpson, Joshua Daly, Katherine J. Baines, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Philip Hugenholtz, Dana Willner, Peter G. Gibson
European Respiratory Journal Mar 2016, 47 (3) 792-800; DOI: 10.1183/13993003.00405-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis
  • Maternal antibiotic use during pregnancy and asthma in children
  • Hyperglycaemia in cystic fibrosis adversely affects BK channel function
Show more Original Articles

Asthma

  • Circadian asthma airway responses are gated by REV-ERBα
  • Long-term trends of asthma, allergic rhinitis and atopic eczema in Finnish men
  • Mepolizumab for severe asthma: the REALITI-A study
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society